Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
GLP 1 Drug Biosimilar Market Size, Share & Trends Analysis by Reference Biologic (Semaglutide Biosimilar, Liraglutide Biosimilar, Exenatide Biosimilar, Dulaglutide Biosimilar), by Formulation (Injectable Pen, Oral Tablet, Patch & Implant), by Distribution (Retail Pharmacy, Mail-Order & Specialty Pharmacy, Hospital & Clinic), and Segment Forecasts, 2026 to 2035 GLP-1 biosimilars are biological medicines developed to be highly similar in quality, safety, and efficacy to the originator GLP-1 receptor agonists, such as semaglutide, liraglutide, and dulaglutide
Landmark studies show average weight loss of 14-18% of baseline body weight over 68 weeks at therapeutic doses
Recurrent or stubborn infections need testing to confirm Candida species and resistance patterns
Ready-to-Drink (RTD) Protein Shakes Subsegment is Driving the GLP-1 Companion Nutrition Market The ready-to-drink (RTD) protein shakes subsegment is emerging as one of the strongest drivers in the GLP-1 companion nutrition market, driven by unmatched convenience and ease of consumption
Polycystic ovary syndrome creates insulin resistance that partially counteracts GLP-1 effects
US$ 23.21
US$ 21.24
US$ 24.58
US$ 28.11
US$ 27.22
